MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
Converge Bio, a developer of AI platforms for biotech and pharmaceutical companies, announced it is using its ConvergeAB platform, an antibody design and optimization solution, to improve the development of cancer treatments through artificial intelligence–driven design. The platform allows researchers to generate and refine therapeutic approaches using prompt-based interactions, enabling faster iteration in drug development.
ConvergeAB is designed to analyze biological data and suggest modifications that could enhance treatment effectiveness. The company said, " AI-powered ConvergeAB produced an upgraded version of an established cancer therapy without a human in the loop, and only 10 top sequences had to be tested in the lab, offering a more efficient path to refining existing drug offerings, with less reliance on traditional trial-and-error methods." This offers a single prompt to generate up to 100,000 antibody candidates.
According to Converge Bio, the approach can be applied to existing therapies, helping researchers optimize treatment strategies without starting from scratch. The platform is intended to support scientists in identifying improvements more quickly than traditional research methods. AI is increasingly being used in biotechnology to accelerate drug discovery and development.
Posted by MedCloudInsider Editors on 05/05/20260 comments
Conscientia Health, a healthcare organization delivering integrated health services through AI-powered telehealth and hybrid care models, has launched a virtual primary care platform designed to combine mental and physical healthcare services using artificial intelligence. The telehealth offering provides patients with access to integrated care through a single virtual environment, supporting services such as primary care consultations, mental health support, and ongoing care management. The platform uses AI to assist with patient engagement, care coordination, and data analysis. Powered by AI and advanced technology, the platform offers all-in-one integrative care features and is able to analyze integrated datasets, streamline workflows and enable real-time collaboration.
Conscientia Health said the approach is intended to deliver “whole-person care” by connecting different aspects of healthcare that are often managed separately. The system is designed to streamline workflows for providers while improving patient access to services. Healthcare organizations are increasingly adopting virtual care models to expand access and reduce costs.
Posted by MedCloudInsider Editors on 04/27/20260 comments
Waltham Pet Science Institute has developed new artificial intelligence–supported risk assessment tool is being introduced to help detect early signs of periodontal disease in dogs. The system analyzes clinical and behavioral data to identify dogs at risk of developing gum disease, one of the most common health issues in companion animals, and predicts which dogs are most at risk. By providing early warnings, the tool is intended to enable veterinarians and pet owners to take preventive action before the condition progresses.
The institute said, "the network confirms the importance of key risk factors (breed and size, age, head shape, and quality of home dental care), quantifies the probability of a dog having periodontal disease based on the presence of these factors, and shows strong performance in predicting which dogs are at high risk."
Designed to integrate with veterinary workflows, supporting routine checkups and ongoing health monitoring, the goal is to improve diagnosis and treatment planning by identifying risk factors that may not be immediately visible. Veterinary care is increasingly adopting digital tools to improve preventive health outcomes. This advancement could transform how periodontal disease is diagnosed, managed, and prevented.
Posted by MedCloudInsider Editors on 04/27/20260 comments
10x Genomics, a life science technology company, has introduced Atera, a platform designed to deliver whole-transcriptome spatial analysis with single-cell sensitivity at scale. The platform combines hardware, software, and analytical tools to help researchers capture and interpret complex biological data at scale. Atera is intended to support applications such as genomics research, drug discovery, and disease analysis by providing more detailed insights into cellular behavior, marking a fundamental shift in how biology is analyzed and understood.
10x Genomics focuses on tools for analyzing biological systems, and the new platform is designed to improve how scientists study interactions at the molecular and cellular levels. The company said the system enables more comprehensive data collection and streamlined analysis workflows. Advances in life sciences research increasingly depend on the ability to generate and interpret large volumes of biological data. Atera is engineered to enable large-scale whole-transcriptome spatial studies across both fresh-frozen and FFPE tissue, supporting diverse applications in both discovery and translational research.
Posted by MedCloudInsider Editors on 04/21/20260 comments
Eclipsebio, a biotechnology company combining AI-powered sequence design, rapid prototyping, and sequencing-based analytics to support RNA drug development, has introduced eCOMPASS, an artificial intelligence–enabled platform designed to support RNA therapeutic development by integrating computational analysis with laboratory processes. The platform uses a lab-in-the-loop approach, combining AI models with experimental data to guide research and refine results in real time. The system is intended to help scientists design experiments, analyze outcomes, and iterate more efficiently during drug development. The platform combines the design, make, and test core capabilities to create a single integrated workflow.
Eclipsebio focuses on RNA-based technologies, and the new platform is designed to improve how researchers identify and validate therapeutic targets. By linking AI-driven insights with lab workflows, the company aims to accelerate discovery timelines and reduce trial-and-error processes. Biopharmaceutical companies are increasingly adopting AI to enhance drug discovery and development.
Posted by MedCloudInsider Editors on 04/21/20260 comments
Core Solutions, a leader in AI-powered solutions for behavioral health and development, has introduced Cx360 Enterprise: The Intelligent Care Record, a platform designed to modernize data management and clinical workflows in behavioral health settings. The system integrates artificial intelligence to help providers capture, organize, and analyze patient information more effectively. The platform is intended to support clinical decision-making, streamline documentation, and improve coordination across care teams. Focused on behavioral health, the platform integrates AI to record and reflect on how care is delivered to individuals, providing healthcare workers with effective ways to manage and configure workflows as well as gain valuable and ethical insights.
Core Solutions focuses on electronic health record (EHR) systems for behavioral health organizations. The new offering is designed to address challenges such as fragmented data, manual processes, and the need for more actionable insights in patient care. The company said, "The Intelligent Care Record brings forward insight in a way that is usable, transparent, and aligned with real clinical workflows, which ultimately supports better care and stronger organizational performance."
The Intelligent Care Record is also intended to support compliance and reporting requirements, which are often complex in behavioral health environments. Healthcare providers are increasingly adopting AI-enabled tools to improve care delivery and operational efficiency.
Posted by MedCloudInsider Editors on 04/13/20260 comments
Ada Health, a clinical expertise and AI insights-driven service provider, announced it has secured a patent for a clinical layer designed to make large language models safer for use in healthcare applications. The technology, Ada's hybrid clinical AI architecture, acts as an intermediary between AI models and clinical use cases, applying medical validation, safety checks, and contextual controls to AI-generated outputs. The goal is to reduce risks associated with using general-purpose language models in clinical decision support and patient interactions. Ada's reasoning engine acts as a guardrail to improve accuracy and preserve rigor, offering a fully auditable clinical reasoning system.
Ada Health focuses on digital health tools that support symptom assessment and care guidance. The patented approach is intended to ensure that AI systems operate within medically appropriate boundaries and align with clinical standards. Healthcare organizations are increasingly exploring generative AI, but concerns remain around accuracy, safety, and regulatory compliance. The patent allows Ada to extend its hybrid approach across pharma and healthcare systems where safety and explainability are of utmost importance.
Posted by MedCloudInsider Editors on 04/13/20260 comments
Clinical AI, a healthcare technology company developing AI solutions to improve clinical trial execution, has announced the launch of its MAIA Prescreening solution on the Google Cloud Marketplace, targeting improved efficiency in clinical trial recruitment. The launch enables healthcare organizations to deploy AI-driven patient screening workflows directly through Google Cloud. The platform uses artificial intelligence to analyze patient data and identify candidates who may qualify for clinical studies. By automating prescreening, the system is designed to help research organizations reduce manual review processes and accelerate enrollment timelines.
MAIA Prescreening integrates with healthcare data systems to evaluate patient eligibility based on study criteria. The platform also supports interactive virtual assistants and avatar deployments, trial simulations, financial document review, language translation and lab information management systems. The solution is intended to support faster identification of potential participants while improving accuracy in matching patients to trials. Clinical trial recruitment remains a significant challenge for healthcare organizations, often delaying research timelines and increasing costs.
Posted by MedCloudInsider Editors on 04/06/20260 comments
GC Biopharma, a biopharmaceutical company focused on manufacturing plasma derivatives, announced a new technology designed to improve the safety profile of intravenous immunoglobulin (IVIG) therapies by detecting prothrombotic impurities. The method enhances its ability to identify trace impurities that may increase the risk of blood clotting in patients receiving IVIG treatments. These therapies are widely used to treat immune deficiencies and autoimmune conditions, making safety a critical concern in manufacturing and quality control. The enhanced assay incorporates a selective IgG Blocker, suppressing non-specific protein reactions ensuring a precise measurement of FXI regardless of the IgG concentration.
GC Biopharma said the detection technology is intended to strengthen product consistency and reduce potential adverse effects associated with thrombotic events. The approach focuses on improving analytical precision during the production process. Biopharmaceutical manufacturers are increasingly investing in advanced quality control technologies to meet regulatory standards and ensure patient safety.
Posted by MedCloudInsider Editors on 04/06/20260 comments
Lunit, a leader in clinical AI-cancer diagnostics, and CellCarta, a global CRO laboratory, announced a strategic collaboration aimed at accelerating the use of artificial intelligence in digital pathology for companion diagnostic (CDx) development. The partnership will combine Lunit’s AI-based image analysis technology with CellCarta’s laboratory and biomarker services. The goal is to support pharmaceutical companies in developing companion diagnostics that help match patients with targeted therapies based on biomarker data. The collaboration aims to integrate Lunit SCOPE AI digital pathology products with CellCarta workflows to support biomarker strategy, image analysis and CDx readiness.
Digital pathology involves analyzing tissue samples using high-resolution imaging and computational tools. By applying AI models to these images, the companies aim to improve the identification of disease patterns and biomarkers relevant to treatment decisions. Companion diagnostics play a growing role in precision medicine, particularly in oncology, where therapies are increasingly tailored to specific patient characteristics. Under the collaboration, initial focus areas include de-risking, translational and clinical workflows, platform-agnostic deployment and a real-world global pilot.
Posted by MedCloudInsider Editors on 03/30/20260 comments
Atlantic Health, a leading not-for-profit health care system, is using artificial intelligence agents from Artera, an agentic healthcare company, to improve colonoscopy screening rates and address gaps in preventive care. The AI agents are designed to engage patients through automated outreach, helping identify individuals due for screening and encouraging them to schedule appointments. The system uses patient data and communication workflows to support follow-ups and reduce missed screenings. Preparation for a colonoscopy can be complex and overwhelming, leading to patient confusion and high cancellation rates. Artera's AI-agents simplify this process with a standardized, AI-driven and digital-first experience.
Colonoscopy screening is a key method for early detection of colorectal cancer, but healthcare providers often face challenges in ensuring patients complete recommended tests. Atlantic Health said the AI-driven approach is intended to improve adherence by streamlining communication and reducing administrative workload. Healthcare systems are increasingly adopting AI tools to support patient engagement and population health initiatives. With automated efficiency, the time spent on manual calls has drastically reduced, allowing healthcare professionals to maximize schedules for high-level patient care.
Posted by MedCloudInsider Editors on 03/30/20260 comments
Perplexity and b.well Connected Health, a data-rich digital health platform, announced a partnership to integrate verified health data into AI-powered search, with the goal of improving the accuracy and personalization of health-related responses. The integration will allow Perplexity’s AI search platform to draw on b.well’s curated health data, which includes clinical records, care information and wellness data. The approach is intended to provide users with more relevant and personalized health insights while maintaining data accuracy.
This integration allows Perplexity users to securely connect medical records, ask questions to receive grounded results based on their own health history, understand lab results, medications and conditions and prepare for appointments while making informed decisions. The experience is focused on patient privacy and control.
b.well focuses on aggregating healthcare data from providers, payers and digital health tools, giving users a unified view of their health information. By combining this data with AI search capabilities, the companies aim to enhance how individuals access and understand health information. AI-driven search tools are increasingly being used to answer health-related questions, raising concerns about accuracy and reliability. The launch builds on b.well's broad strategy to enable next-generation AI-powered health assistants.
Posted by MedCloudInsider Editors on 03/23/20260 comments